Zensana™ (ondansetron HCl) oral spray contains the most widely prescribed anti-emetic compound, ondansetron.  It has the potential to be a more convenient alternative to the tablet, intravenous and suppository forms of the drug, which are marketed by GlaxoSmithKline under the brand name Zofran®.

Zensana™ would be the first oral spray 5-HT3 antagonist that conveniently delivers full metered doses of ondansetron, potentially allowing patients to gain and maintain protection from chemotherapy-, radiation- and post-operatively induced nausea and vomiting more rapidly than the tablet formulation.  Many patients receiving chemo- and radiation therapy have difficulty swallowing and are potentially unable to tolerate other therapies, known as anti-emetics, which are intended to prevent nausea and vomiting. The convenience of drug delivery via an oral spray may be a desirable alternative to tablets and other forms of ondansetron for patients suffering from severe nausea and vomiting. 

In August 2007, NovaDel announced a sublicense agreement of Zensana™ to Par Pharmaceuticals from Hana Biosciences.  This sublicense agreement affords Par the commercialization rights to Zensana™ in the U.S. and Canada.  NovaDel retains the rights for ondansetron oral spray outside of North America and is actively pursuing commercial partners for these markets.

Imitrex®, Zofran® and Requip® are registered trademarks of GlaxoSmithKline. Ambien® is a registered trademark of Sanofi-Aventis. Zanaflex® is a registered trademark of Acordia Therapeutics Inc. ZolpiMist™ and NitroMist™ are trademarks of NovaDel Pharma, Inc. Zensana™ is a pending trademark of Hana Biosciences.